GALECTIN THERAPEUTICS INC financial data

Symbol
GALT on Nasdaq
Location
Norcross, GA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 18.6 % -88.4%
Debt-to-equity -111 % +24.6%
Return On Equity 32.2 % -49.2%
Return On Assets -269 % -65.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.5M shares +2.73%
Common Stock, Shares, Outstanding 64.5M shares +3.47%
Entity Public Float 112M USD +77.8%
Common Stock, Value, Issued 64K USD +3.23%
Weighted Average Number of Shares Outstanding, Basic 64.2M shares +3.09%
Weighted Average Number of Shares Outstanding, Diluted 64.2M shares +3.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 23.5M USD -30.3%
General and Administrative Expense 5.68M USD -3.3%
Operating Income (Loss) -29.1M USD +26.3%
Nonoperating Income (Expense) -8.16M USD -48%
Net Income (Loss) Attributable to Parent -37.3M USD +17.2%
Earnings Per Share, Basic 0 USD/shares +19.2%
Earnings Per Share, Diluted 0 USD/shares +19.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.5M USD -57.4%
Assets, Current 12.7M USD -55.6%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 37K USD +42.3%
Other Assets, Noncurrent 136K USD -55.6%
Assets 12.9M USD -55.6%
Accounts Payable, Current 5.39M USD +92.8%
Employee-related Liabilities, Current 1.1M USD +3.87%
Accrued Liabilities, Current 5.04M USD -56.5%
Liabilities, Current 136M USD +440%
Operating Lease, Liability, Noncurrent 7K USD -87.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 136M USD +12.3%
Retained Earnings (Accumulated Deficit) -427M USD -9.61%
Stockholders' Equity Attributable to Parent -125M USD -33%
Liabilities and Equity 12.9M USD -55.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.69M USD +36.5%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 64.5M shares +3.47%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.5M USD -57.4%
Deferred Tax Assets, Valuation Allowance 90.3M USD +15.2%
Deferred Tax Assets, Gross 90.3M USD +15.2%
Operating Lease, Liability 37K USD +15.6%
Lessee, Operating Lease, Liability, to be Paid 38K USD +15.2%
Property, Plant and Equipment, Gross 74K USD 0%
Operating Lease, Liability, Current 37K USD +15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 19K USD +5.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 22K USD +10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 63.1M USD +2.65%
Preferred Stock, Shares Issued 1.21M shares -2.02%
Preferred Stock, Shares Authorized 1.74M shares 0%
Additional Paid in Capital 301M USD +2.16%
Preferred Stock, Shares Outstanding 1.21M shares -2.02%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.06M USD -12.7%
Interest Expense 3.38M USD +167%